Amgen fends off biosimilar for arthritis drug Enbrel

You are here: Home > Biotech > Current Article

Amgen fends off biosimilar for arthritis drug Enbrel

By Marissa Nall / Friday, August 16th, 2019 / Comments Off on Amgen fends off biosimilar for arthritis drug Enbrel

In a court victory with broad implications for the biotech industry, Amgen secured protection through 2028 for its top-selling arthritis drug Enbrel, furthering its defense against encroachment by biosimilar competitors. The ruling Aug. 8 in a New Jersey District Court permanently blocked sales of a biosimilar developed by Sandoz, a German division of Swiss multinational…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.